Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-6236 in Advanced Solid Tumors with RAS Mutations
NCT05379985Phase 2Recruiting
- Sponsor
- Revolution Medicines
- Start
- May 2022
- Primary completion
- May 2027
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of daraxonrasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), solid tumor (advanced stage), sponsored by Revolution Medicines. Started May 2022; status: recruiting.
02
Drugs
daraxonrasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05379985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05379985.